HUE056551T2 - Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken - Google Patents

Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken

Info

Publication number
HUE056551T2
HUE056551T2 HUE14854852A HUE14854852A HUE056551T2 HU E056551 T2 HUE056551 T2 HU E056551T2 HU E14854852 A HUE14854852 A HU E14854852A HU E14854852 A HUE14854852 A HU E14854852A HU E056551 T2 HUE056551 T2 HU E056551T2
Authority
HU
Hungary
Prior art keywords
fxs
asd
acamprosate
activation
animal models
Prior art date
Application number
HUE14854852A
Other languages
English (en)
Inventor
Craig Erickson
Debomoy Lahiri
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of HUE056551T2 publication Critical patent/HUE056551T2/hu

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/48Nerve growth factor [NGF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/20Screening for compounds of potential therapeutic value cell-free systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14854852A 2013-10-14 2014-10-14 Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken HUE056551T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361890756P 2013-10-14 2013-10-14

Publications (1)

Publication Number Publication Date
HUE056551T2 true HUE056551T2 (hu) 2022-02-28

Family

ID=52828619

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14854852A HUE056551T2 (hu) 2013-10-14 2014-10-14 Az akamprozát alkalmazása az ERK 1-2 aktiváció modulálására az FXS és az ASD állati modelljeiben, valamint az FXS és ASD diagnózissal rendelkezõ egyéneken

Country Status (11)

Country Link
US (2) US10634677B2 (hu)
EP (1) EP3058371B1 (hu)
JP (1) JP6637414B2 (hu)
AU (1) AU2014337504B2 (hu)
CA (1) CA2926645C (hu)
DK (1) DK3058371T3 (hu)
HU (1) HUE056551T2 (hu)
PL (1) PL3058371T3 (hu)
PT (1) PT3058371T (hu)
RU (1) RU2696481C2 (hu)
WO (1) WO2015057736A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3058371T3 (pl) 2013-10-14 2021-11-08 Indiana University Research And Technology Corporation Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd
WO2017147044A1 (en) * 2016-02-22 2017-08-31 Indiana University Research And Technology Corporation Peptides and methods for treatment of neurodegenerative diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316635B1 (en) * 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP0946179B1 (en) 1996-03-11 2003-09-17 Eli Lilly And Company Use of olanzapine or a pharmaceutically acceptable salt for the manufacture of a medicament for the treatment of autism and mental retardation
PL198599B1 (pl) 1998-07-06 2008-07-31 Nsgene As Izolowany kwas nukleinowy neublastyny, wektor ekspresji, izolowana komórka, polipeptyd, sposób wytwarzania polipeptydu, oczyszczony polipeptyd, kompozycja, zastosowanie polipeptydu, sekwencja kwasu nukleinowego primera, sposób wytwarzania peptydów, sposób wytwarzania peptydu neublastyny, syntetyczny gen, peptyd neublastyny, przeciwciało, zastosowanie czynnika neurotroficznego neublastyny i zastosowanie kwasu nukleinowego
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6627625B1 (en) 1999-08-16 2003-09-30 Revaax Pharmaceuticals, Llc Treatment of behavioral disorders with β-lactam compounds
SE0300586L (sv) 2003-03-04 2004-09-05 Forskarpatent I Syd Ab Diagnos av autism
ES2897422T3 (es) 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
WO2008060375A2 (en) 2006-10-06 2008-05-22 The Regents Of The University Of Californina Upregulating bdnf levels to mitigate mental retardation
CA2670116C (en) * 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
NZ577436A (en) 2006-12-22 2012-05-25 Genentech Inc Death receptor 6 (dr6) antagonist inhibiting the binding of dr6 to amyloid precursor protein (app), and uses thereof in treating neurological disorders
WO2008112772A2 (en) * 2007-03-14 2008-09-18 Baylor Research Institute Gene expression in peripheral blood mononuclear cells from children with diabetes
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090239888A1 (en) * 2008-02-12 2009-09-24 Wisconsin Alumni Research Foundation Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation
KR101390607B1 (ko) * 2008-07-14 2014-05-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 귀 질환 치료를 위한 제어 방출형 아폽토시스 조절 조성물 및 방법
PT2395990E (pt) 2009-02-12 2015-02-09 Univ Indiana Res & Tech Corp Material e métodos de tratamento de transtornos do desenvolvimento incluindo autismo comórbido e idiopático
US8008539B1 (en) 2009-03-19 2011-08-30 University Of South Florida Generation of transgenic human soluble amyloid precursor protein alpha expressing mice
US20130052644A1 (en) 2010-04-30 2013-02-28 Baltazar Gomez-Mancilla Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS)
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US9597312B2 (en) 2010-08-19 2017-03-21 Cognitive Research Enterprises, Inc. Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators
RU2465273C2 (ru) 2010-08-31 2012-10-27 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
AU2013293167B2 (en) * 2012-07-22 2019-04-18 Indiana University Research And Technology Corporation Modulation sAPP, sAPP alpha and BDNF levels in individuals diagnosed with FXS and ASD
PL3058371T3 (pl) 2013-10-14 2021-11-08 Indiana University Research And Technology Corporation Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd

Also Published As

Publication number Publication date
RU2016118551A (ru) 2017-11-21
US10634677B2 (en) 2020-04-28
JP2016536293A (ja) 2016-11-24
AU2014337504B2 (en) 2020-01-30
EP3058371A4 (en) 2017-04-19
CA2926645C (en) 2022-10-25
RU2016118551A3 (hu) 2018-07-24
JP6637414B2 (ja) 2020-01-29
US20200225233A1 (en) 2020-07-16
DK3058371T3 (da) 2021-08-02
US20160266120A1 (en) 2016-09-15
WO2015057736A1 (en) 2015-04-23
PT3058371T (pt) 2021-07-26
CA2926645A1 (en) 2015-04-23
PL3058371T3 (pl) 2021-11-08
US11733243B2 (en) 2023-08-22
RU2696481C2 (ru) 2019-08-02
EP3058371A1 (en) 2016-08-24
EP3058371B1 (en) 2021-06-16

Similar Documents

Publication Publication Date Title
IL239961A0 (en) Useful real-time diagnostic results
HK1208296A1 (en) Methods and apparatus to determine impressions using distributed demographic information
EP2827707A4 (en) NON-HUMAN ANIMAL DEPRESSION MODELS AND METHODS OF USE THEREOF
EP2987106A4 (en) ACQUIRING AND ANALYZING PHYSIOLOGICAL DATA
SG11201602236SA (en) Animal models and therapeutic molecules
PL2941195T3 (pl) Urządzenie do pomiaru analitów w skórze
IL264559A (en) Methods and reagents for the evaluation of gestational diabetes
GB2525771B (en) Methods and systems related to electrosurgical wands
EP2914987A4 (en) DEVICE AND METHOD FOR VISUALIZING FORMING FEATURES
PL3004833T3 (pl) Ulepszenia związane z pobieraniem próbek
GB2516343B (en) Improvements in and relating to ophthalmoscopes
GB201322094D0 (en) Methods and compositions relating to alzheimers disease
IL244590A0 (en) Anti-epcam antibodies and methods of use
HK1222864A1 (zh) 的小分子調節劑和其使用方法
HK1222562A1 (zh) 用於醫學診斷的組合物及方法
EP2957925A4 (en) STREAMING STOMOGRAPHIC PROCESS AND STREAMING TOMOGRAPHY DEVICE
HK1219636A1 (zh) 經改善的皮膚及頭皮診斷裝置及方法
EP3064161A4 (en) Ultrasonic probe and ultrasonic treatment device
EP3060061A4 (en) Use of probiotics in meat
EP2979645A4 (en) ULTRASONIC DIAGNOSTIC DEVICE AND ULTRASONIC DIAGNOSTIC METHOD
EP2853591A4 (en) HEMATOMIC HEMAZONE CELL LINE HLCZ01 AND USES THEREOF
PL3058371T3 (pl) Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd
EP3060163A4 (en) Early determination of pregnancy status in ruminants
EP2971131A4 (en) METHODS AND MATERIALS USING SIGNALING PROBES
EP2981556A4 (en) HYALURONIC ACID BIOPOLYMERS ETHYLSULFONATED AND METHODS OF USE